Tesamorelin vs HGH

One of these is the hormone. The other asks the body to produce it. That is the whole decision, and the table above cannot express it, because the two are not sold in the same unit.

HGH is recombinant human growth hormone — a 191-amino-acid polypeptide identical to the pituitary hormone, acting directly at the growth-hormone receptor and downstream on IGF-1. Supplying it bypasses the pituitary entirely, which means the pattern of exposure is whatever the administration schedule makes it, not what the gland would have produced.

Tesamorelin is a stabilised GHRH analogue of 44 amino acids, modified with a trans-3-hexenoic acid group to resist enzymatic degradation. It acts a step upstream, at the pituitary, so any release stays subject to the feedback and pulsatility of the axis itself. Its human evidence is unusually specific: nearly all of it comes from one indication, HIV-associated lipodystrophy, with visceral adipose tissue as the measured endpoint. That is a narrow base to generalise from, and it should be read as narrow.

So the choice is between direct receptor agonism and upstream stimulation with the gland still in the loop.

Handling separates them too. Both are stored at 2–8 °C, but a reconstituted tesamorelin vial has a far shorter working window than most peptides on this site. Purity, sizes, price per milligram and current availability above are read from the live catalogue at page load.

Both are supplied for laboratory research only. Neither is sold for human or veterinary use.